RxDoctor Payments Data

Amanda Worner

Family · Omaha, NENPI 1780014944

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.0% of the total across 355 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 43 manufacturers, the largest accounting for just 14.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,901 and has fallen 93.9% since, to $177 in 2024. Among family clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,339in general payments, 2019–2025

Across 355 payments — averaging $17.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$933
  • AbbVie$908
  • Novo Nordisk$574
  • Bayer$501
  • Amgen$372
  • Lilly USA, LLC$335
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$6,27699%
  • Education$631%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,339 in reported general payments places this provider in the 95th percentile of 809 family providers in Nebraska.

See all family providers in Nebraska

Medicare billing

Part B allowed, 2024
$13,042
Medicare patients
66
Services billed
190

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide11$18,472
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen17$548
Atorvastatin Calcium69$453
Rosuvastatin Calcium28$359
Losartan Potassium38$296
Amlodipine Besylate58$294
Pantoprazole Sodium18$284
Metoprolol Succinate28$275
Simvastatin24$258
Levothyroxine Sodium37$233
Hydrochlorothiazide35$229
Omeprazole18$141
Atenolol23$135
Ramipril12$135
Montelukast Sodium11$116

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$574$18,47211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 809 family providers in Nebraska.

Other family in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →